Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
iQ3Corp. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
iQ3Corp's earnings available for a low price, and how does
this compare to other companies in the same industry?
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as iQ3Corp has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.
Show me the analysis anyway
The future performance of a company is measured in the same way as past
performance, by looking at estimated
and how much profit it is expected to make.
Future estimates come from
professional analysts. Just like forecasting the weather, they don’t always get
Expected Capital Markets industry annual growth in earnings.
Earnings growth vs Low Risk Savings
expected to grow at an
Unable to compare iQ3Corp's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
Unable to compare iQ3Corp's earnings growth to the Australia market average as no estimate data is available.
Unable to compare iQ3Corp's revenue growth to the Australia market average as no estimate data is available.
Unable to determine if iQ3Corp is high growth as no earnings estimate data is available.
Unable to determine if iQ3Corp is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
iQ3Corp's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Dr. George Syrmalis, M.D., Ph.D., FACNP, MAAPP, has been Chief Executive Officer at FarmaForce Limited since November 24, 2015 and has been its Director since November 24, 2015. He has been the Chief Executive Officer at iQ3Corp Limited since May 21, 2015. Dr. Syrmalis serves as an Executive Chairman and Group Chief Executive Officer of IQnovate Ltd. He has been the Chief Executive Officer and Executive Director at iQX Limited since November 24, 2014. He is the Member of Scientific Advisory Board at Glucose Biosensor System (Greater China) Holdings Inc. He has been an Executive Director of IQnovate Ltd. since March 8, 2011. He is a Sydney Sider, who is trained in Nuclear Medicine-radiation immunology. Dr. Syrmalis founded and led as Chief Executive Officer and Chairman of The Bionuclear Group SA, from 1995 to 2005 incorporating Antisoma SA, Bionuclear Institute of Diagnosis and Therapy SA, Bionuclear Research and Development SA and Vitalcheck SA. Dr. Syrmalis developed a business model by addressing unmet clinical needs and leveraging on synergies between Bionuclear Group companies, they are Antisoma SA, Bionuclear Institute for Diagnosis and Therapy SA, Bionuclear Research and Development SA and Vitalcheck SA. Since 2005 onwards, he continued his career as Advisor to the Biopharmaceutical industry, advising on translational clinical trials, biomarkers and strategy to commercialize novel biologic entities in the areas of oncology, epilepsy and autoimmune diseases. Dr. Syrmalis had been a Non-Executive Director at FarmaForce Limited. He is a Member of the American Academy of Pharmaceutical Physicians.
George's compensation has increased whilst company is loss making.
George's remuneration is higher than average for companies of similar size in Australia.
Chief Executive Officer
Board of Directors
Independent Non-Executive Chairman
Who owns this company?
Recent Insider Trading
No 3 month open market individual insider trading information.
What Kind Of Investor Owns Most Of iQ3Corp Ltd (ASX:IQ3)?
View our latest analysis for iQ3Corp ASX:IQ3 Ownership Summary, August 2nd 2019 What Does The Institutional Ownership Tell Us About iQ3Corp? … ASX:IQ3 Income Statement, August 2nd 2019 Hedge funds don't have many shares in iQ3Corp. … Private Company Ownership We can see that Private Companies own 36%, of the shares on issue.
Should You Be Pleased About The CEO Pay At iQ3Corp Ltd's (ASX:IQ3)
This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. … How Does George Syrmalis's Compensation Compare With Similar Sized Companies. … We examined a group of similar sized companies, with market capitalizations of below AU$277m.
Does iQ3Corp Limited's (ASX:IQ3) Past Performance Indicate A Stronger Future?
See our latest analysis for iQ3Corp Were IQ3's earnings stronger than its past performances and the industry? … I like to use the ‘latest twelve-month’ data, which annualizes the most recent half-year data, or in some cases, the latest annual report is already the most recent financial year data. … ASX:IQ3 Income Statement May 19th 18 We can further assess iQ3Corp's loss by looking at what the industry has been experiencing over the past few years.
iQ3Corp Ltd provides capital raising and corporate advisory services to listed and unlisted companies in the life science industry. It offers advisory services on initial public offerings, listings, private equity, mergers and acquisitions, structured finance, strategic matters, restructuring and capital structure, capital raising, and corporate finance. The company also provides sell-side, buy-side, and NSX nominated advisory services. It serves corporations, partnerships, institutions, governments, and individuals. The company was founded in 2012 and is based in Sydney, Australia.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.